Recent Updates
Recently added Catalysts
ELAN Negative Sentiment Score: 30/100

ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Elanco Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Elanco Animal Health on behalf of its stockholders due to concerns over potential violations of federal securities laws and unlawful business practices. This follows Elanco's recent announcement about delayed FDA approval timelines for key products, Zenrelia and Credelio Quattro, which resulted in a significant drop in its stock price. The firm encourages stockholders who may have suffered losses or have information related to these claims to reach out for assistance. The situation presents possible risks for investors concerning the company's compliance and market performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Potential for future FDA approvals with updated timelines.
  • Opportunity for legal recourse for affected stockholders.

CONCERNS & RISKS

  • Elanco's stock price fell significantly by 20.53%.
  • Investigation into potential violations of federal securities laws.

Full Press Release Details

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) on behalf of Elanco stockholders. Our investigation concerns whether Elanco has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On June 27, 2024, Elanco issued a press release "announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024.
On this news, Elanco's stock price fell $3.69 per share, or 20.53%, to close at $14.28 per share on June 27, 2024.
If you purchased or otherwise acquired Elanco shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the ongoing investigation against Elanco?

Bragar Eagel & Squire, P.C. is investigating potential claims against Elanco for possible securities law violations and unlawful business practices.

Why did Elanco's stock price drop recently?

Elanco's stock fell 20.53% after the company revised FDA approval timelines for Zenrelia and Credelio Quattro.

When is Zenrelia expected to get FDA approval?

Zenrelia is expected to receive FDA approval in the third quarter of 2024.

How can Elanco shareholders get more information?

Shareholders can contact Brandon Walker or Marion Passmore via email or phone for more information.

What does Bragar Eagel & Squire, P.C. specialize in?

The firm specializes in representing investors in commercial and securities litigation.

Last updated: Jul 2, 2024